DiviTum™ scientific results presented at the European Heamatology Conference
Two abstracts from the University Hospital in Olomouc, Czech Republic presented at the European Heamatology Conference in Amsterdam, June 14-17, demonstrated the value of using DiviTum™ as a prognostic biomarker and it’s unprecedented sensitivity.
Dr Prochazka and research colleagues demonstrated that DiviTum™ extends the detection range of thymidine kinase (TK) compared to conventional, older methods, and that DiviTum™ enables improved quantification of TK. A strong correlation between pre-treatment TK levels and lymphoma stage and aggressiveness was also found.
Professor Bacovsky and research colleagues showed that there is a significant correlation between serum levels of TK measured by DiviTum™ and markers reflecting activity of multiple myeloma (e.g. B2M and LDH). They also found significantly higher values of TK in the group of patients with multiple myeloma (stage I, II or III) compared to patients in stage MGUS (Monoclonal Gammopathy of Undetermined Significance) meaning that DiviTum™ can be used as a predictor for multiple myeloma